Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia
about
Alemtuzumab for patients with chronic lymphocytic leukaemiaChronic lymphocytic leukaemia--the haematologic basis for diagnosis and treatment.Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy.Alemtuzumab in clinical practice: a British Columbia experience.Alemtuzumab for B-cell chronic lymphocytic leukemia.Morphological and immunophenotypic features of chronic lymphocytic leukemia.Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.Alemtuzumab: a novel monoclonal antibody.Update on prophylaxis and therapy of infection in patients with chronic lymphocytic leukemia.B-chronic lymphocytic leukemia: practical aspects.Choosing first-line therapy for chronic lymphocytic leukemia.Monoclonal antibodies in the treatment of chronic lymphoid leukemias.Stem cell transplantation for chronic lymphocytic leukaemia.Monoclonal antibody therapy of leukaemias and lymphomas.Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.The evolving role of alemtuzumab in management of patients with CLL.Alemtuzumab in CLL and other lymphoid neoplasms.Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational useAlemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia.Alemtuzumab in the treatment of chronic lymphocytic lymphoma.What is the best frontline therapy for patients with CLL and 17p deletion?Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis.Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia.Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics.Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection.Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.Monoclonal antibodies in the treatment of human B-cell malignancies.Alemtuzumab in chronic lymphocytic leukemia.Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative DisordersExpression of fatty acid-binding protein 4/aP2 is correlated with plaque instability in carotid atherosclerosisApplications of monoclonal antibodies for the treatment of hematological malignancies
P2860
Q24203628-72407EE8-27FE-4266-9349-847877EE0AEAQ33343670-28ED3FE5-5AE0-4D26-BD2C-94FCCCD1D9C4Q33365360-EC73C00B-8E6A-4450-9A84-2694FD554055Q33378464-861ACDCA-43DE-4676-9FA3-B83EFB042AC0Q33380135-30A7811D-3BC5-4B58-B1AC-A5636BBE4980Q34326557-8A4344E4-0D55-4060-BAEF-88824FC71FA8Q34440110-85D05516-546A-4C20-8549-20C6520CE834Q34452735-3F091E82-DEBD-42EA-9629-D64E1E2DB081Q34734324-B6D1BEE5-DC6D-4FC4-B1FE-A7B2278A48B0Q34803868-9F08487A-232D-470E-BD97-8842B6F0426CQ35124844-DA17B59F-265C-4691-849F-8B1B8402868DQ35752823-8C7D7AE3-4E28-4EC2-9923-5002569C1BC1Q36003096-D7415B80-BC99-4246-8D97-2B050D5BD2CCQ36239669-487DF058-2A3E-4AFE-9D68-3CD4C2BFC655Q36276344-A404AFD8-6434-420A-BDA2-BF043FE503FFQ36292883-F699714E-924E-4099-92E0-EBF6B1775A51Q36659824-4236F472-685A-4B6A-8B4B-A22928611E5DQ36768605-E50020FC-ED25-4499-80AD-53F3A50B8CDBQ36832113-0C241841-FB5E-40C2-8ACA-948A8AB25877Q36985872-9438A069-23B8-4F76-BE0E-1EF60F7406C3Q37134417-5A6468BE-559E-41E0-A8F3-BE1553DAEC70Q37820433-96CB2150-8811-4E5E-A3EB-EC2B679E6576Q38911206-01FABCA3-2C57-4E05-A0A5-FEC3691132EDQ39264020-D6A15FEF-1D37-43CE-8AAB-6E8AEED568EDQ40577635-FF4027E3-D22F-4084-9F6D-19ED87CEF4ADQ43430617-B7A072D9-AAED-4CE2-84D7-BDAE5ED470B2Q44324002-F2694D7D-1A59-4A39-93DF-20617AC18488Q44397235-129697E5-1885-4785-8404-6D0CEF0CDE02Q44750591-AE08F839-23C0-4240-A952-A5544E85181BQ45244361-83A32BFF-7982-44D1-9D83-0DBBBFD73795Q45862709-E929ABD1-7969-48CA-B407-3F79BA5B8A27Q51092788-F6E79B47-B4C3-47CF-BD72-672C58415FC2Q53572903-94975374-CC12-4363-8B45-BB94B6BF2433Q57053368-248E5B2E-9251-4EB6-BBB8-F62CAC85A312Q57315836-655B73B9-0670-4C00-88F5-3045C6781928Q57904664-D2664D7D-17D0-4D96-809D-02918C68F2BF
P2860
Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia
description
im April 1996 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 April 1996
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 1996
@uk
name
Humanized CD52 monoclonal anti ...... chronic lymphocytic leukaemia
@en
Humanized CD52 monoclonal anti ...... chronic lymphocytic leukaemia
@nl
type
label
Humanized CD52 monoclonal anti ...... chronic lymphocytic leukaemia
@en
Humanized CD52 monoclonal anti ...... chronic lymphocytic leukaemia
@nl
prefLabel
Humanized CD52 monoclonal anti ...... chronic lymphocytic leukaemia
@en
Humanized CD52 monoclonal anti ...... chronic lymphocytic leukaemia
@nl
P2093
P1476
Humanized CD52 monoclonal anti ...... chronic lymphocytic leukaemia
@en
P2093
A Osterborg
A S Fassas
D Catovsky
H Mellstedt
P304
P356
10.1046/J.1365-2141.1996.450989.X
P407
P577
1996-04-01T00:00:00Z